Displaying drugs 11001 - 11025 of 12185 in total
PF-04418948
Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
Investigational
Matched Description: … Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers). ... Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And …
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Description: … MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. ... It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] …
Tesofensine
Investigational
Sitimagene ceradenovec
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
Investigational
Matched Description: … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high ... grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy …
LY2275796
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Investigational
Matched Description: … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. ... LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of …
TC-5231
TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder). TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.
Investigational
Matched Description: … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention ... 5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a …
FF-10501-01
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Matched Description: … FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer ... [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in …
SS1(dsFv)-PE38
SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma).
Investigational
Matched Description: … SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. ... SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 …
BBM-H803
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
Matched Description: … BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed …
XL844
XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and...
Investigational
Matched Description: … XL844 is a solid. ... response to a variety of DNA damaging agents. ... XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in …
CNS-5161
CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Investigational
Matched Description: … as a novel compound for the treatment of neuropathic pain. ... CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials …
PX-478
PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer
and small cell lung cancer that express HIF-1 alpha.
Investigational
Matched Description: … PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical …
Refametinib
Investigational
Pascolizumab
Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Investigational
Matched Description: … Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma …
Reversin 121
Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance.
Experimental
Matched Description: … Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug …
Petesicatib
Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers).
Investigational
Matched Description: … Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers …
KW-6356
KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.
Experimental
Matched Description: … KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822] …
TNB-383B
TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.
Investigational
Matched Description: … TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody. …
RP-L301
RP-L301 is a lentiviral vector containing the human liver and erythroid pyruvate kinase gene.
Investigational
Matched Description: … RP-L301 is a lentiviral vector containing the human liver and erythroid pyruvate kinase gene. …
KT-253
KT-253 is a selective heterobifunctional small molecule degrader of mouse double minute 2 (MDM2).
Investigational
Matched Description: … KT-253 is a selective heterobifunctional small molecule degrader of mouse double minute 2 (MDM2). …
STP-707
STP-707 is a small interfering RNA (siRNA) targeting TGF-Beta1 and COX-2 mRNA.
Investigational
Matched Description: … STP-707 is a small interfering RNA (siRNA) targeting TGF-Beta1 and COX-2 mRNA. …
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16 ... of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a ... dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells …
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
Matched Description: … It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device ... It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important ... Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a …
Displaying drugs 11001 - 11025 of 12185 in total